FY2024 EPS Forecast for Oncolytics Biotech Cut by Analyst

Oncolytics Biotech Inc. (TSE:ONC) – Investment analysts at Raymond James reduced their FY2024 earnings per share (EPS) estimates for Oncolytics Biotech in a research note issued on Tuesday, November 12th. Raymond James analyst R. Sarugaser now anticipates that the company will post earnings of ($0.44) per share for the year, down from their prior forecast of ($0.38). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.47) EPS.

Oncolytics Biotech Trading Down 2.1 %

ONC stock opened at C$1.38 on Friday. The company has a market cap of C$106.07 million, a P/E ratio of -3.63 and a beta of 1.35. Oncolytics Biotech has a twelve month low of C$1.15 and a twelve month high of C$2.32. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09. The business has a fifty day moving average of C$1.50 and a 200-day moving average of C$1.45.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.